- FBRX Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
CORRESP Filing
Forte Biosciences (FBRX) CORRESPCorrespondence with SEC
Filed: 12 May 20, 12:00am
Tocagen Inc.
4445 Eastgate Mall, Suite 200
San Diego, CA 92121
(858)412-8400
May 12, 2020
VIA EDGAR
Division of Corporation Finance
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-3628
Attention: | Julie Sherman Brian Cascio Courtney Lindsay Irene Paik |
Re: | Request for Effectiveness for Tocagen Inc. |
Registration Statement on Form S-4 (FileNo. 333-237371) |
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Tocagen Inc. (the “Registrant”) hereby respectfully requests that the effectiveness of the above-referenced Registration Statement be accelerated to 4:00 p.m. Eastern Time, on May 13, 2020, or as soon thereafter as practicable. The Registrant respectfully requests that you notify Karen Deschaine of Cooley LLP of such effectiveness by telephone at (858)550-6088.
If you have any questions or comments regarding the foregoing, please do not hesitate to contact Ms. Deschaine at the telephone number above.
Very truly yours, | ||||
Tocagen Inc. | ||||
By: | /s/ Mark Foletta | |||
Name: | Mark Foletta | |||
Title: | Chief Financial Officer |
cc: Karen Deschaine, Cooley LLP